Sector
PharmaceuticalsOpen
₹26.77Prev. Close
₹28.17Turnover(Lac.)
₹1.14Day's High
₹29.54Day's Low
₹26.7752 Week's High
₹30.8852 Week's Low
₹6.27Book Value
₹-2.74Face Value
₹10Mkt Cap (₹ Cr.)
14.17P/E
0EPS
0Divi. Yield
022 Aug 2024
12:00 AM
BookCloser
1 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
11 Jan 2025
12:00 AM
EGM
22 Aug 2024
12:00 AM
AGM
Announcement Date: 22 Aug, 2024
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 5.24 | 5.24 | 5.24 | 5.24 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -5.89 | -5.95 | -6.18 | -8.03 |
Net Worth | -0.64 | -0.71 | -0.94 | -2.79 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 0.47 | 0.15 | 0 | 0.25 |
yoy growth (%) | 212.02 | 0 | -100 | -86.57 |
Raw materials | -0.31 | -0.09 | 0 | -0.24 |
As % of sales | 67.2 | 60.93 | 0 | 94.21 |
Employee costs | -0.21 | -0.1 | -0.05 | -0.06 |
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -0.26 | -0.24 | -0.24 | -0.49 |
Depreciation | -0.01 | 0 | 0 | 0 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | 0.01 | -0.14 | 0.01 | -0.16 |
Other operating items |
| Y/e 31 Mar | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 212.02 | 0 | -100 | -86.57 |
Op profit growth | 6.49 | -1.4 | -60.68 | 346.75 |
EBIT growth | 10.95 | -0.86 | -50.68 | 256.19 |
Net profit growth | 15.28 | -2.01 | -81.87 | 868.92 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,744.85 | 132.89 | 4,18,647.96 | 1,181.05 | 0.77 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,001.1 | 76.85 | 1,59,310.35 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,478.5 | 25.66 | 1,19,409.63 | 1,438.15 | 0.88 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,137.55 | 58.21 | 1,06,184.18 | 485 | 0.89 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,413.35 | 51.49 | 99,569.64 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
N Krishnaniah
Independent Director
Meena Kumari Pilli
Non Executive Director
Swapneswar Mishra
Company Sec. & Compli. Officer
Sandan Grover
Independent Director
Mr Reddeppa Gundluru
Independent Director
D. Rakesh Reddy
WTD & Additional Director
Sadhanala Venkata Rao
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Venmax Drugs & Pharmaceuticals Ltd
Summary
Venmax Drugs & Pharmaceuticals Limited, (VDPL) was initially incorporated as Private Limited Company under the name and style of Yenkay Medico Private Limited, on 28 September, 1998. The Company thereafter changed its name to Yenkey Drugs & Pharmaceuticals Private Limited on 18 January, 1995. It became a Public Limited Company on February 3, 1995 with Yenkey Drugs & Pharmaceuticals Limited. Finally, the Company changed its name to Venmax Drugs & Pharmaceuticals Limited on April 13, 2009. For the past six months, Company focused on establishing chain of Medical Stores with a brand name as Ananya Pharma under the Venmax Drugs & Pharma Limited, with the backing support of Formulations plant (Suzichem Labs). Initially, the Company engaged in the business of pharmaceutical products, drug intermediaries & APIs etc. The Company is engaged in the business of IT & ITES services.
Read More
What is the Venmax Drugs & Pharmaceuticals Ltd share price today?
The Venmax Drugs & Pharmaceuticals Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹27.04 today.
What is the Market Cap of Venmax Drugs & Pharmaceuticals Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Venmax Drugs & Pharmaceuticals Ltd is ₹14.17 Cr. as of 09 May ‘25
What is the PE and PB ratio of Venmax Drugs & Pharmaceuticals Ltd?
The PE and PB ratios of Venmax Drugs & Pharmaceuticals Ltd is 0 and -10.27 as of 09 May ‘25
What is the 52 Week High and Low of Venmax Drugs & Pharmaceuticals Ltd?
The 52-week high/low is the highest and lowest price at which a Venmax Drugs & Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Venmax Drugs & Pharmaceuticals Ltd is ₹6.27 and ₹30.88 as of 09 May ‘25
What is the CAGR of Venmax Drugs & Pharmaceuticals Ltd?
Venmax Drugs & Pharmaceuticals Ltd's CAGR for 5 Years at N/I%, 3 Years at N/I%, 1 Year at N/I%, 6 Month at 328.12%, 3 Month at -1.16% and 1 Month at -4.99%.
What is the shareholding pattern of Venmax Drugs & Pharmaceuticals Ltd?
The shareholding pattern of Venmax Drugs & Pharmaceuticals Ltd is as follows:
Promoters - 23.14 %
Institutions - 0.15 %
Public - 76.72 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
